Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (Nasdaq: SLP) announced the release of IPFsym version 1A, a quantitative systems pharmacology software aimed at developing treatments for idiopathic pulmonary fibrosis (IPF). The software, sponsored by a leading pharmaceutical company, aims to enhance treatment options in a market worth over $2 billion. Key features include a virtual population of over 700 subjects and important biomarkers like forced vital capacity and high-resolution computed tomography. The company will also host a webinar for further insights on IPFsym.
Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will participate in the Craig-Hallum 18th Annual Institutional Investor Conference on June 2, 2021. The conference will be virtual, featuring over 150 public companies and allowing institutional clients to engage in one-on-one 30-minute meetings. Attendance is by invitation only. Simulations Plus has been a leading provider of simulation software and consulting services for drug discovery for 25 years, serving clients across the globe.
Simulations Plus (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on May 20, 2021, at 1:30 p.m. ET. CFO Will Frederick will also participate in one-on-one meetings throughout the day. This conference will feature presentations from over 350 public and private company management teams, providing an excellent opportunity for shareholders and investors.
For inquiries or to schedule meetings, contact Hayden IR at slp@haydenir.com. More details can be found on the Needham conference website.
Simulations Plus, Inc. (Nasdaq: SLP) announced that its common stock has been approved for trading on The Nasdaq Global Select Market effective May 13, 2021. This milestone reflects the company's successful growth investments that have enhanced its financial performance and global scale. CEO Shawn O’Connor highlighted that this step will increase visibility and liquidity for existing and future shareholders. Simulations Plus has been providing modeling and simulation solutions for over 25 years, serving clients in pharmaceutical and biotechnology sectors.
Simulations Plus, Inc. (Nasdaq: SLP) launched version 10.2 of its flagship machine learning platform, ADMET Predictor, now marketed as APX.2. This update introduces significant enhancements, including a High Throughput Pharmacokinetic (HTPK) Simulation Module, new dosing options, and improved mutagenic risk rules. The enhancements boost software performance, making it easier for pharmaceutical companies to predict drug properties. Dr. David Miller highlighted the software's expanded capabilities, while Dr. Eric Jamois noted increased revenue from the product line, indicating strong market adoption.
Simulations Plus, Inc. (Nasdaq: SLP) has renewed access to its DILIsym software platform for the U.S. Food and Drug Administration (FDA). This unlimited licensing package allows FDA employees across various divisions to utilize the software, enhancing drug safety assessments related to drug-induced liver injury (DILI). Key leaders in drug development will discuss the software's application in a panel on April 29, 2021. DILIsym aids in predicting DILI risk, guiding crucial drug development decisions, and has been utilized in several regulatory submissions.
Simulations Plus, Inc. (Nasdaq: SLP) announced successful initial results from a collaborative research with a major pharmaceutical company, evaluating generative chemistry technology via their Artificial Intelligence-driven Drug Design (AIDD) Module. Out of 10 candidate molecules synthesized, 8 exhibited an IC50 below 1 µM, with the most potent showing values below 100 nM. The predictive accuracy for biological activity was noteworthy, and solubility measures closely aligned with estimations, showcasing the potential of the AIDD technology in drug discovery.
Simulations Plus, Inc. (Nasdaq: SLP) will announce its financial results for Q2 FY 2021, ending February 28, after market close on April 12, 2021. A conference call will be held the same day at 4:15 p.m. ET, accessible via registration or by phone. The company, a leading provider of modeling software and consulting services, supports drug discovery and development for pharmaceutical and regulatory sectors worldwide. Further details are available on their website.
Simulations Plus (Nasdaq: SLP) has established a Scientific Advisory Board (SAB) within its DILIsym Services (DSS) division. The SAB will guide the development of RENAsym, a kidney injury quantification software platform. Key members include experts from Rutgers, Georgia University, and UC San Diego. The SAB’s formation follows a decade of success with the DILIsym initiative, which has helped develop the DILIsym software for liver injury assessment. RENAsym version 1A is expected in late 2021, enhancing DSS's capability in kidney safety assessments for drug developers.
Simulations Plus, Inc. (Nasdaq: SLP) successfully launched the 2021 MIDD+ Scientific Conference, a two-day event highlighting customized modeling and simulation for pharmaceutical scientists. Key topics included the drug development process and the integration of machine learning and population PK/PD approaches. Over 1,000 participants registered, featuring speakers from U.S. FDA and international health agencies. The event also focused on gender disparities in science, with awards recognizing outstanding contributions in the field. Simulations Plus continues to lead in providing innovative tools and services for drug development.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
